DeutschNewstral
Article
Seattle Times on 2018-11-01 18:16
Seattle biotech stalwart ZymoGenetics prepares for year-end closure
Related news
Seattle Genetics buys biotech factory in Bothellseattletimes.com- Seattle biotech Adaptive buys San Francisco firmseattletimes.com
- Seattle biotech PhaseRx files to go publicseattletimes.com
- Seattle biotech Silverback Therapeutics prices upsized IPOseattletimes.com
Seattle Genetics operations chief resigns to lead stealthy Seattle biotechbizjournals.com- Seattle startup Sana Biotech prices big stock offeringseattletimes.com
- Seattle biotech firm Silverback Therapeutics aims for $100M IPOSeattle Times
- Promising COVID-19 treatment sends Seattle biotech company’s stock soaringSeattle Times
- Seattle biotech PhaseRx prices IPO at $5 a shareseattletimes.com
At Seattle biotech Acucela, acrimony breaks into openold.seattletimes.com- Biotech roundup: How many drugs has Seattle developed?bizjournals.com
- AG Ferguson, with tribes and historic groups, sues feds over Seattle National Archives closureseattletimes.com
- End Seattle politicking over homelessnessSeattle Times
- Seattle Genetics' exec: Here's how to stay an independent biotech in Seattlebizjournals.com
- Boulder biotech acquires Seattle companybizjournals.com
- Longtime Sounders stalwart Zach Scott to retire at the end of this seasonseattletimes.com
- Seattle prepares for health consequences of wildfire smokeSeattle Times
- Macy’s downtown closure triggers memories of a bygone SeattleSeattle Times
- Brandi Carlile prepares for ‘emotional’ run with Seattle Symphonyseattletimes.com
- Seattle Metro buses rerouted due to Aurora Bridge closureseattletimes.com